EFFECTS OF CHLOROQUINE ON PATIENTS WITH CUTANEOUS PORPHYRIA OF THE "SYMPTOMATIC" TYPE.
D000596:Amino Acids; D001219:Aspartate Aminotransferases; D056486:Chemical and Drug Induced Liver Injury; D002738:Chloroquine; D002965:Classification; D004796:Clinical Enzyme Tests; D005441:Fluids and Secretions; D005955:Glucosephosphate Dehydrogenase Deficiency; D005958:Glucosephosphates; D006505:Hepatitis; D006801:Humans; D007982:Levulinic Acids; D008099:Liver / Q000502:physiology*; D008660:Metabolism; D010336:Pathology; D011164:Porphyrias; D011166:Porphyrins; D011758:Pyrroles; D014116:Toxicology; D014556:Urine
D000596:Amino Acids; D005958:Glucosephosphates; D007982:Levulinic Acids; D011166:Porphyrins; D011758:Pyrroles; D002738:Chloroquine; D001219:Aspartate Aminotransferases; C032246:levulinic acid
AMINO ACIDS; ASPARTATE AMINOTRANSFERASE; CHLOROQUINE; CLASSIFICATION; ENZYME TESTS; EXCRETION; GLUCOSEPHOSPHATE DEHY- DROGENASE DEFICIENCY; HEPATITIS, TOXIC; LEVULINIC ACID; LIVER FUNCTION; METABOLISM; PATHOLOGY; PORPHYRIA; PORPHYRINS; PYRROLES; TOXICOLOGIC REPORT; URINE